Financial FlexibilityConnect Biopharma Holdings is eligible to receive milestone payments up to approximately $110M and royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China, which could provide financial flexibility to invest further in development without diluting shareholders.
Market OpportunityThe large market opportunity in COPD and asthma, along with rademikibart's unique mechanism of action, suggests it could become the therapy of choice in both acute and chronic settings.
Strategic PartnershipsThe company's cash runway extends into 2027, which allows for the readout of Phase 2 studies in acute asthma and COPD, positioning them strongly for future strategic partnerships.